Zen Technologies Limited Grant of 1,27,500 Employee Stock Options Under 2021 Scheme

Zen Technologies Limited announced the approval for the grant of 1,27,500 Employee Stock Options (ESOPs) under its 2021 Employee Stock Option Plan. This grant was approved via a circular resolution by the Nomination and Remuneration Committee on March 30, 2026. The exercise price for these options is set at ₹250/- per option, which is above the face value but below the prevailing market price as of the grant date.

ESOP Grant Approval Details

Zen Technologies Limited has officially communicated the approval of a substantial grant of Employee Stock Options (ESOPs) to eligible employees. This decision was formalized by the Nomination and Remuneration Committee through a circular resolution passed on March 30, 2026.

The total number of options granted under the “Zen Technologies Limited Employee Stock Option Plan – 2021” amounts to 1,27,500 ESOPs. The total equity shares covered by this issuance will be 1,27,500 shares, each with a face value of Re. 1/-.

Pricing and Vesting Structure

The Pricing formula/Exercise Price for these options has been fixed at Rs. 250/- (Rupees Two hundred and Fifty Only) per option. It is noted that this price is set to be more than the face value of the company’s equity shares and less than the prevailing Market Price as of the date of the grant.

Regarding vesting and exercise:

  • Options vested: Options will start vesting after a period of one year from the date of grants.
  • Time to exercise: Options shall be exercised within 2 years from the date of the respective vesting period.

Scheme Administration

The grant administration and implementation of the “Zen Technologies Limited Employee Stock Option Plan 2021” are managed by the Nomination and Remuneration Committee. This process is executed through the Zen Technologies Limited Employees Welfare Trust, in accordance with the established Scheme criteria.

The company confirmed that there are no subsequent changes or cancellations of such options, and the issuance will result in no impact on diluted earnings per share.

Source: BSE

Previous Article

Jubilant Pharmova Reminder Issued for Unclaimed Dividends and Share Transfer to IEPF Authority

Next Article

Torrent Pharma Sale of Equity Shares in Associate Company, UNM Foundation